Turing Pharmaceuticals will soon offer discounts to hospitals for its toxoplasmosis-fighting drug, the company announced, but some say the proposed price reductions are not enough.
An incorrect isomer of the kinase inhibitor bosutinib is circulating in the biomedical research community, potentially throwing doubt on study results.